Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1388792

Cover Image

PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1388792

Myasthenia Gravis Treatment Market, By Drug Class, By Age Group, By Distribution Channel, By Country, and By Region -Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

PUBLISHED:
PAGES: 303 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 3250
PDF (5 User License)
USD 4650
PDF (Enterprise User License)
USD 5650

Add to Cart

REPORT HIGHLIGHT

Myasthenia gravis treatment market size was valued at USD 2,012.43 Million in 2022, expanding at a CAGR of 9.4% from 2023 to 2030.

Myasthenia gravis (MG) is a type of chronic, rare, and progressive neuromuscular disorder that causes weakness of the head, eye, limb, spinal, and respiratory muscles. Antibodies against the acetylcholine receptor (AchR) that prevent proper electrical signal transmission from nerves to muscles are produced in these autoimmune disorders. Additionally, facial paralysis, drooping of eyelids, double vision, and difficulty in walking are symptoms of myasthenia gravis. These diseases are diagnosed by numerous tests including blood tests for antibodies, Magnetic Resonance Imaging (MRI), edrophonium test, repetitive nerve stimulation test, and Computed Tomography (CT).

Myasthenia Gravis Treatment Market- Market Dynamics

Rising prevalence and increasing awareness about myasthenia gravis worldwide driving the market growth

The rising global incidence of myasthenia gravis, the adoption of innovative treatments for myasthenia gravis, and increased knowledge about early diagnosis are the primary drivers driving the development of the myasthenia gravis treatment market. Moreover, the growing focus of pharmaceutical companies on the development of novel drugs for disease treatment is witnessing significant growth in the myasthenia gravis treatment market. Additionally, various medications, including immunosuppressants and monoclonal antibodies, are being tested and developed for their efficacy in treating myasthenia gravis. However, side effects associated with the drugs used for treating myasthenia gravis are expected to restrain the market growth shortly. Furthermore, rising awareness about myasthenia gravis among healthcare professionals and patients is majorly contributing to the increase in demand for effective treatments. In line with this, individuals are more likely to seek treatment and diagnosis for myasthenia gravis as more people become aware of its signs and risks. Healthcare professionals are also becoming more knowledgeable about the disease and its available treatments, leading to an increased demand for efficient treatments.

Myasthenia Gravis Treatment Market- Key Insights

  • As per the analysis shared by our research analyst, the global myasthenia gravis treatment market is estimated to grow annually at a CAGR of around 9.4% over the forecast period (2023-2030)
  • The myasthenia gravis treatment industry is projected to grow at a significant rate due to the rising awareness about myasthenia gravis among healthcare professionals and patients
  • Based on drug class segmentation, monoclonal antibodies was predicted to show maximum market share in the year 2022
  • Based on distribution channel segmentation, hospital pharmacies was the leading type in 2022

Government initiatives to increase consciousness regarding myasthenia gravis and improve healthcare infrastructure are fueling the market growth.

Myasthenia Gravis Treatment Market- Segmentation Analysis:

The global myasthenia gravis treatment market is segmented on the basis of drug class, age group, distribution channel, and region.

The market is divided into five categories based on drug class: thymectomy, monoclonal antibodies, cholinesterase inhibitors, rapid immunotherapies, chronic immunomodulators, and others. The monoclonal antibodies segment is expected to hold the highest market share due to the high precision in treating myasthenia gravis and improved efficacy. The rising use of monoclonal antibodies aims to reduce lifelong exposure to corticosteroids and improve long-term results.

The market is divided into three categories based on distribution channels: drugstore and retail pharmacies, hospital pharmacies, and online providers. The hospital pharmacies segment is likely to maintain its dominance over the forecast period. The segment is attributed to access to the high demand for advanced equipment and a large patient pool for MG treatment in hospital settings. Additionally, the availability of a broad range of treatment options in such facilities has increased patient visits for treatment and diagnosis. The rising investment in state-of-the-art healthcare infrastructures is the prime factor contributing to its large share.

Myasthenia Gravis Treatment Market- Geographical Insights

Geographically, this market is analyzed into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further segmented as per the nations bringing business. North America has the biggest market share for myasthenia gravis therapy. The growth in autoimmune disease evaluation, the existence of significant companies providing innovative medicines, the high incidence of myasthenia gravis, and the accessibility of improved healthcare infrastructure are all expected to drive the myasthenia gravis treatment industry. Moreover, Asia-Pacific is accounted to witness notable growth due to the increase in awareness campaigns regarding autoimmune diseases & available treatment options, rising number of autoimmune diseases, and rising investments for the development of effective treatment options for myasthenia gravis. In addition, in emerging economies upsurge in healthcare expenditure is anticipated to provide lucrative opportunities for market expansion, driving the myasthenia gravis treatment market.

Myasthenia Gravis Treatment Market- Competitive Landscape:

Several organizations such as the government are counseling individuals regarding autoimmune diseases. E-commerce has become a vital tool for large and small businesses across the globe, due to the increase in the preference of consumers for online shopping as compared to traditional purchasing methods. Additionally, several animations through health apps to educate people regarding the usage of medications and myasthenia gravis have contributed toward the myasthenia gravis treatment market growth. Moreover, major market players have adopted strategic alliance, acquisition, product approval, expansion, and agreement as key developmental strategies to enhance the product portfolio of the myasthenia gravis treatment industry. For instance, in March 2021, Grifols a global healthcare company to improve the health and well-being of people worldwide announced to acquire GigaGen Inc. to boost a novel method to generate a broad range of immunoglobulins.

Recent Developments:

For instance, in April 2023, CSL Behring, a global biotechnology company, has received FDA approval for a 50mL/10gm prefilled syringe for Hizentra. CSL Behring offers a comprehensive variety of prefilled syringe sizes to satisfy the specific needs of persons suffering from Primary Immunodeficiency as well as Chronic Inflammatory Demyelinating Polyneuropathy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET KEY PLAYERS

  • F.Hoffmann-La Roche AG
  • Alexion Pharmaceutical Inc.
  • Zydus Lifesciences Limited
  • Grifols SA
  • Shire plc
  • Kedrion
  • Avadel Pharmaceuticals, Plc.
  • Octapharma AG
  • Novartis
  • Bausch Health Companies Inc.
  • Pfizer, Inc.
  • AbbVie Inc.
  • GlaxoSmithKline Plc.

GLOBALMYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS

  • Thymectomy
  • Monoclonal Antibodies
  • Cholinesterase Inhibitors
  • Rapid Immunotherapies
  • Chronic Immunomodulators
  • Others

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP

  • Below 55 years
  • Above 55 years

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • Drug store and retail pharmacies
  • Hospital pharmacies
  • Online providers

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA
Product Code: ANV1846

Table of Contents

1. Myasthenia Gravis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Myasthenia Gravis Treatment Market Snippet by Drug Class
    • 2.1.2. Myasthenia Gravis Treatment Market Snippet by Age Group
    • 2.1.3. Myasthenia Gravis Treatment Market Snippet by Distribution Channel
    • 2.1.4. Myasthenia Gravis Treatment Market Snippet by Country
    • 2.1.5. Myasthenia Gravis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Myasthenia Gravis Treatment Key Market Trends

  • 3.1. Myasthenia Gravis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Myasthenia Gravis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Myasthenia Gravis Treatment Market Opportunities
  • 3.4. Myasthenia Gravis Treatment Market Future Trends

4. Myasthenia Gravis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Myasthenia Gravis Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Myasthenia Gravis Treatment Market Landscape

  • 6.1. Myasthenia Gravis Treatment Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Myasthenia Gravis Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022&2030 (%)
    • 7.1.2. Thymectomy
    • 7.1.3. Monoclonal Antibodies
    • 7.1.4. Cholinesterase Inhibitors
    • 7.1.5. Rapid Immunotherapies
    • 7.1.6. Chronic Immunomodulators
    • 7.1.7. Others

8. Myasthenia Gravis Treatment Market - By Age Group

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Age Group, 2022&2030 (%)
    • 8.1.2. Below 55 years
    • 8.1.3. Above 55 years

9. Myasthenia Gravis Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022&2030 (%)
    • 9.1.2. Drug store and retail pharmacies
    • 9.1.3. Hospital pharmacies
    • 9.1.4. Online providers

10. Myasthenia Gravis Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022&2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Myasthenia Gravis Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Myasthenia Gravis Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Myasthenia Gravis Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Myasthenia Gravis Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Myasthenia Gravis Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Myasthenia Gravis Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. F.Hoffmann-La Roche AG
    • 11.2.2. Alexion Pharmaceutical Inc.
    • 11.2.3. Zydus Lifesciences Limited
    • 11.2.4. Grifols SA
    • 11.2.5. Shire plc
    • 11.2.6. Kedrion
    • 11.2.7. Avadel Pharmaceuticals, Plc.
    • 11.2.8. Octapharma AG
    • 11.2.9. Novartis
    • 11.2.10. Bausch Health Companies Inc.
    • 11.2.11. Pfizer, Inc.
    • 11.2.12. AbbVie Inc.
    • 11.2.13. GlaxoSmithKline Plc.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
Product Code: ANV1846

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Myasthenia Gravis Treatment Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Myasthenia Gravis Treatment Market, by Drug Class2018-2030 (USD Million)
  • TABLE Myasthenia Gravis Treatment Market: Age GroupSnapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Age Group
  • TABLE Global Myasthenia Gravis Treatment Market, by Age Group2018-2030 (USD Million)
  • TABLE Myasthenia Gravis Treatment Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Myasthenia Gravis Treatment Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Myasthenia Gravis Treatment Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Myasthenia Gravis Treatment Market, by Region 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)

List of Figures

  • FIGURE Myasthenia Gravis Treatment Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Drug Class segment market share analysis, 2022&2030
  • FIGURE Drug Class segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Age Group segment market share analysis, 2022&2030
  • FIGURE Age Group segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2022&2030
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022&2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Europe Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Asia Pacific Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Latin America Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Middle East and Africa Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE Germany Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE India Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE Brazil Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE Saudi Arabia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!